C-3PGUautologous cellular therapy, MSC-NTF cells, neurodegeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The goal of this two-part clinical trial is: 1\) to evaluate the safety and efficacy of Debamestrocel - MSC-NTF (NurOwn) compared to placebo in participants with early symptomatic ALS and moderate disease presentation in ALS; followed by 2) further evaluation by providing NurOwn to all participants in an open label extension period. Researchers will compare NurOwn to a placebo (a look-alike substance that contains no drug) to evaluate the efficacy of NurOwn compared to placebo in the treatment of participants with ALS. Participants will: Receive NurOwn or a placebo every 8 weeks for 24 weeks. After that, every participant will receive NurOwn every 8 weeks for an additional 24 weeks. They will visit the clinic approximately every 8 weeks for checkups and tests.
A multidose open-label study with autologous Mesenchymal Stromal Stem Cells Secreting Neurotrophic Factors (MSC-NTF cells) involving 20 participants with progressive MS at multiple investigational study sites.
This study will evaluate the safety and efficacy of repeated administration of NurOwn® (MSC-NTF cells) therapy, which is based on transplantation of autologous bone marrow derived mesenchymal stromal cells (MSC), which are enriched from the patient's own bone marrow, propagated ex vivo and induced to secrete Neurotrophic factors (NTFs). The autologous NurOwn® (MSC-NTF cells) are back-transplanted into the patient intrathecally by standard lumbar puncture where neurons and glial cells are expected to take up the neurotrophic factors secreted by the transplanted cells
This is a multi-center, randomized, double blind, placebo controlled study to evaluate the safety and efficacy of autologous (self) transplantation of Neurotrophic factors-secreting Mesenchymal Stromal Cells (MSC-NTF, NurOwn™) in patients with ALS . MSC-NTF cells are a novel cell-therapeutic approach which is expected to effectively deliver Neurotrophic factors, which are potent survival factors for neurons, directly to the site of damage.
The study will evaluate the safety, tolerability and therapeutic effects of transplantation of escalating doses of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF), in patients with amyotrophic lateral sclerosis (ALS).
The study will evaluate the safety, tolerability and therapeutic effects (preliminary efficacy) of injection of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF), as a possible treatment for patients with Amyotrophic Lateral Sclerosis (ALS) at the early and progressive disease stages.
How many surfaces and how to generate them - Discussions - Brainstorm Brainstorm How many surfaces and how to generate them Discussions Baris October 4, 2012, 9:02am 1 Hi all, I recently started using Brainstorm, and I am analyzing CTF 273 channel MEG data. I have anatomoical files in nii format, acquired by Siemens 3T machine. I am a bit confused about the number of surfaces that I should prepare for the forward model. Particularly, I could not see what the default surfaces I should find as well as the minimum number of required surfaces. I I used BrainVisa as suggested, but it gave errors at
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Brainstorm Distribution, Inc. - Audiovisual Identity Database Search Log in ↓ Personal tools Create account Log in Navigation menu Navigation Main Page Recent Changes Forums Gallery Featured Articles and Media Tutorials Community Portal Random Page Contribute Create a Draft Create a Page Upload File Apply for Writer Requests for Comment Audiovisual Branding Cinema Trailers Commercial Tags Production Logos Sound Logos Splash Screens Startup and Boot Screens Television Idents Informational Bumpers Closed Captioning Bumpers End Screens Home Media Bumpers Rating Bumpers Sponsor Bumpers Telev
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
BrainStorm Announces MOU with Tel Aviv Sourasky Medical Center to Make NurOwn® Available to Patients as a Hospital Exemption Product Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Mult … erstanding (MOU) with The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Sourasky Medical Center (Ichilov Hospital) to explore the possibility of making NurOwn® available to Amyotrophic Lateral Sclerosis (ALS) patients under the provisions of Hospital Exemption regulation. The MOU also covers the participation of Tel Aviv Sourasky Medical Center in the planned Phase 3 trial that will investigate NurOwn in ALS. Th … er which Brainstorm and Tel Aviv Sourasky Medical Center would work together to submit an application to the Israeli Ministry of Health that will allow patient access to NurOwn and is subject to a definitive agreement. The agreement is expected to be formalized in the first half of 2017. "We are pleased to be working with Tel Aviv Sourasky Medical Center and look forward to putting a definitive agreement in place," said Chaim Lebovits , President and CEO of BrainSt … that NurOwn meets the requirements to be a Hospital Exempt product and, if our application is successful, we could potentially make the product available to patients prior to obtaining formal licensure." "Tel Aviv Sourasky Medical Center and BrainStorm have a joint interest in developing a path to bring advanced therapies to patients," said Professor Ronni Gamzu , CEO of Tel Aviv Sourasky Medical Center. "We hope our combined efforts will … Brainstorm Cell Therapeutics to partner with a local medical center in order to apply for HE. About Tel Aviv Sourasky Medical Center Tel Aviv Sourasky Medical Center (Ichilov) is the second largest and one of the most progressive full-service healthcare treatment and research institutions in Israel . The Medical Center draws patie
--> BrainStorm Issues 2024 Letter to Shareholders --> Login Start Free Trial Catalyst Calendar FDA Calendar Track key readouts and FDA decision dates in biotech and pharma. BPW Portfolio Bio Hedge Fund Shots and more... Historical FDA Calendar Review past FDA decisions and clinical readouts. Market Movers Track today's biotech market movers Biotech Earning Calendar Stay updated on biotech earnings. Historical PDUFA Dates Review past PDUFA dates and decisions. PDUFA Calendar Stay ahead of upcoming PDUFA dates Conference Calendar Keep up with biotech events. IPO Upcoming & past IPOs. Bio Pha … p; past IPOs. Bio Pharma Screener Catalyst Sync™ Track biotech catalysts. Hedge Fund Screener Analyze hedge fund holdings. Company Screener Holistic company & pipeline analysis. All Stocks Holdings Explore hedge fund stock data. Heat-Map Market size & sector heat map. Inside Trades Monitor insider trading. Biotech Analyst Ratings Biotech analyst ratings & price targets M&A Tracker Track M&A deals and acquisition targets Resources News Latest biotech news. … l funding sources, including non-dilutive grants and potential partnerships, to fund Phase 3b trial for NurOwn, development of our exosome platform and our operations. Our team's sacrifices, including salary reductions and extended work hours, have been critical in keeping the company moving forward. We remain committed to exploring new opportunities for funding and collaboration to ensure our innovations reach their full potential. Reflecting on Our Mission As we look ahead,
Don't miss out on the opportunity to sponsor 🚀 BrainStorm Summit 2025 and connect with industry leaders, families, researchers, doctors, nonprofits, warriors, and survivors of Pediatric Cancer. TOGETHER WE ARE CREATING A BETTER WAY!!! Mark your calendars for September 2025 and get ready to make an impact! 🚀🧠BrainStorm Summit2025 September 17th-20th #CancelChildhoodCancer #brainstormsummit2025 #pediatricbraincancer | BrainStorm Summit
Amazon.com: Brainstorm ID Supply Skip to Main content Keyboard shortcuts Search alt + / Cart shift + alt + C Home shift + alt + H Orders shift + alt + O Show/Hide shortcuts shift + alt + Z To move between items, use your keyboard's up or down arrows. .us Delivering to Nashville 37217 Update location All Select the department you want to search in All Departments Prime Day Alexa Skills Amazon Devices Amazon Fresh Amazon Global Store Amazon Haul Amazon One Medical Amazon Pharmacy Amazon Resale Appliances Apps & Games Arts, Crafts & Sewing Audible Books & Originals Automotive Parts & Accesso
View Filing Data This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. Print Document Reports Document and Entity Information Statements INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) INTERIM CONDENSED CONSOLIDATED ST … Company estimates the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s consolidated statement of operations. The Company recognizes compensation expense for the value of non-employee awards, which have graded vesting, based on the straight-line method over the requisite servic … ng, based on the straight-line method over the requisite service period of each award. The Company estimates the fair value of restricted shares based on the market price of the shares at the grant date and estimates the fair value of stock options granted using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are, expected stock price volatility and the expected option term. Expected volatility wa … ntation of government grants. The ASU requires entities to recognize government grant income when all eligibility criteria have been met and the related costs have been incurred, clarifying the timing and presentation of such grants within the financial statements. The ASU is effective for annual periods beginning after December 15, 2028 and interim reporting within those annual reporting periods. The company is still evaluating the potential impact of the new standard on its … od Type: instant X - Definition Amount of cost not yet recognized for nonvested award under share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943
--> --> BrainStorm Announces MOU with Tel Aviv Sourasky Medical Center to Make NurOwn® Available to Patients as a Hospital Exemption Product - Mar 1, 2017 --> --> Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS About Progressive MS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Tog … erstanding (MOU) with The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Sourasky Medical Center (Ichilov Hospital) to explore the possibility of making NurOwn® available to Amyotrophic Lateral Sclerosis (ALS) patients under the provisions of Hospital Exemption regulation. The MOU also covers the participation of Tel Aviv Sourasky Medical Center in the planned Phase 3 trial that will investigate NurOwn in ALS. The MOU sets forth the basic terms und … er which Brainstorm and Tel Aviv Sourasky Medical Center would work together to submit an application to the Israeli Ministry of Health that will allow patient access to NurOwn and is subject to a definitive agreement. The agreement is expected to be formalized in the first half of 2017. "We are pleased to be working with Tel Aviv Sourasky Medical Center and look forward to putting a definitive agreement in place," said Chaim Lebovits , President and CEO of BrainSto … that NurOwn meets the requirements to be a Hospital Exempt product and, if our application is successful, we could potentially make the product available to patients prior to obtaining formal licensure." "Tel Aviv Sourasky Medical Center and BrainStorm have a joint interest in developing a path to bring advanced therapies to patients," said Professor Ronni Gamzu , CEO of Tel Aviv Sourasky Medical Center. "We hope our combined efforts will leverage BrainSt … Brainstorm Cell Therapeutics to partner with a local medical center in order to apply for HE. About Tel Aviv Sourasky Medical Center Tel Aviv Sourasky Medical Center (Ichilov) is the second largest and one of the most progressive full-service healthcare treatment and research institutions in Israel . The Medical Center draws patients from through
%PDF-1.7 %���� 1 0 obj >/Metadata 1308 0 R/ViewerPreferences 1309 0 R>> endobj 2 0 obj > endobj 3 0 obj >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��RMo�0 ���Q*`��%� �s��[ � � j~�q�'�ޗ�)���B �l�3�`���BX ���l .%�\��T�_%~�Ǹ0C�� ��{�=�E\�*JZ��2x����"��\F��p�(��eG��)%������uڇ�U@b[ʊ�����}R��� �+ -�������#��n����`4��� �t�} �h����%��-Դ������Y�R�@Z )Kh�S�`& N�; F�]�K���^m:�y�$�JWj��Z�49�����.h��g*E ��Y�t����T"�!�^䶎u��b�3�'�{�@�1Mnۃ��
Haro Hartounian, PhD - BrainStorm – Discover, Innovate, Deliver – Delivering on the Promise of Cellular Therapeutics Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Toggle Overview News Events and Presentations Stock Information Financ
Brainstorm: Better Planning, Collaboration, & Reporting for Core Contributor Work - #6 by antoviaque - Governance - Open edX discussions = 40rem)" rel="stylesheet" data-target="desktop" /> = 40rem)" rel="stylesheet" data-target="discourse-ai_desktop" /> = 40rem)" rel="stylesheet" data-target="discourse-reactions_desktop" /> = 40rem)" rel="stylesheet" data-target="poll_desktop" /> = 40rem)" rel="stylesheet" data-target="desktop_theme" data-theme-id="-2" data-theme-name="horizon"/> Open edX discussions Brainstorm: Better Planning, Collaboration, & Reporting for Core Contributor Work Work
Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February Accessibility Statement Skip Navigation Back to Global Sites +972-77-2005042 Blog Journalists GDPR Send a Release News Products Contact Hamburger menu Send a Release Telephone +972-77-2005042 from 8 AM - 11 PM IL Contact Contact +972-77-2005042 from 8 AM - 11 PM IL --> Request More Information Journalists GDPR --> Request More Information Journalists GDPR Request More Information Journalists GDPR Request More Information Journalists GDPR Brainstorm Cell Therapeutics Secures Second $1 … 799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging … eden United Kingdom United States Do not sell or share my personal information: Submit via [email protected] Call Privacy toll-free: 877-297-8921 Global Sites Asia Brazil Canada Csezh Denmark Finland France Germany India Israel Italie Mexico Middle East Netherlands Norway Poland Portugal Russia Slovakia Spain Sweden United Kingdom United States +972-77-2005042 from 8 AM - 11 PM IL Terms of Use Privacy Policy Information Security Policy Site Map Cookie Settings Cop
BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Ce … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update August 14, 2023 | 13 min read Twitter LinkedIn Facebook Email Print BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegener … osis (ALS) scheduled for September 27, 2023 BrainStorm's Biologics License Application (BLA) for NurOwn has a Prescription Drug User Fee Act (PDUFA) action date targeted to occur by December 8, 2023 Company prepares for ADCOM date presentation and builds resources for FDA review and decision Conference call and webcast at 8:00 a.m. Eastern Time today NEW YORK , Aug. 14, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer … acy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive MS and was supported by a grant from the National MS Society (NMSS). Notice Regarding Forward-Looking Statements This press release contains "forward-lookin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs November 8, 2021 | 7 min read Twitter LinkedIn Facebook Email Print BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseas … lyn. She served an internship in Internal Medicine at Danbury Hospital and residency in Adult Neurology at Long Island Jewish Medical Center, becoming Chief Resident. She also has received training in Bioethics at Columbia University . Dr. Thacker is a Fellow of the New York Academy of Medicine. Dr. Thacker commented: "I am excited to join BrainStorm's leadership team during such a transformational period for the Company. BrainStorm's unique approaches to the treatm … acy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple sclerosis (MS) and was supported by a grant from the National MS Society (NMSS). For more information, visit the company's website at www.bra … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Portfolio - Brainstorm Ventures Portfolio Team Menu Portfolio All Fund I Fund II Fund III Fund IV AIO World’s first all-in-one native AI platform with zero integrations for restaurants Anvil Robotics Physical AI development and mass production platform Aravo Third party governance, compliance and risk management cloud-based software Bedrock Materials Sodium-ion battery technology for electric vehicles Shut down Bid4Assets Online real estate auction site that has sold over 100K properties nationwide Bleeding Edge Edge computing data centers BrainGrid Empowers serious vibe coders to build, evolv … ctions between loved ones Acquired by GreatCall Me.com Early social network web application Acquired by Apple Menta Embedded B2B payments for LATAM Momos Customer engagement platform for restaurants MyPoppins Professional cleaning and household services platform Merged with Clintu NachoNacho Subscription marketplace and management platform OpenTable World’s leading provider of online restaurant reservations IPO OrkestaPay eCommerce payment orchestration platform Outcome Agent … mission-critical challenges for Fortune 500 companies and governments Uniscape Award-winning globalization management software Acquired by Trados Vacatia Vacation ownership and rental marketplace Varda Space Industries Varda designs and builds commercial space infrastructure such as in-orbit factories and reentry capsules Voiceplug Voice AI order taking for restaurants Wavedash Play the latest games with no dowloads by utilizing cutting edge browser technology Webacy Managin
--> --> Investors & Media - BrainStorm Cell Therapeutics - Press Releases --> --> Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS About Progressive MS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Toggle Overview News Events & Presentations Stock Information Financial Reports … ation of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm received U.S. FDA clearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03
View Filing Data This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. Print Document View Excel Document Cover Document and Entity Information Financial Statements CONSOLIDATED BALANCE SHEETS CONSOLIDATED BALANCE SHEETS (Parenthetical) CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) CONSOLIDATED STATEMENTS OF CASH FLOWS Notes to Financial Statements GENERAL SIGNIFICANT ACCOUNTING POLICIES RES … to enable accelerated development of NurOwn® for the treatment of ALS. To fund the Phase 3b study and ALS priorities, the Company is actively exploring various options to raise capital including non-dilutive grants and capitalizing on its exosome technology. At the same time, the Company reduced and refocused resources by streamlining clean room operations and undertaking a targeted reduction in headcount of approximately 30 percent. Positions most critical to the imple … cted Stock, Nonvested at end of period 304,896 217,027 272,596 Weighted Average Grant Date Fair Value, Nonvested at beginning of period $ 5.01 $ 5.49   Granted 2.27 3.66   Vested 2.91 5.03   Forfeited 4.09     Weighted Average Grant Date Fair Value, Nonvested at end of period $ 2.86 $ 5.01 $ 5.49 Weighted Average Remaining Contractual Term (Years), Nonvested 1 year 3 months 25 days 1 year 4 months 24 days 1 year 2 months 23 days X - Definition The num … : na Period Type: duration X - Definition Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb. … ype: na Period Type: duration X - Definition The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + References Reference 1: http://www.xbrl.org/2
BRAINSTORM CELL THERAPEUTICS INC._September  30, 2025 0001137883 --12-31 2025 Q3 false 0.91 0.19 8673908 11008047 1.80 0.51 4793026 5309796 0.067 P1Y3M11D http://www.brainstorm-cell.com/20250930#BankOfIsraelOfficialMonetaryInterestRateMember http://www.brainstorm-cell.com/20250930#BankOfIsraelOfficialMonetaryInterestRateMember http://www.brainstorm-cell.com/20250930#BankOfIsraelOfficialMonetaryInterestRateMember http://www.brainstorm-cell.com/20250930#BankOfIsraelOfficialMonetaryInterestRateMember 0001137883 bcli:July2023WarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:Meas … 12 months (or for such shorter period that the registrant was required to submit such files).  Yes   ☒   No  ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and ̶ … mpensation to employees and to directors: Under the 2014 Plans, the Company may award stock options to certain employees, officers, directors, and/or service providers. The stock options vest in accordance with such conditions and restrictions determined by the GNC Committee. Stock options: The Company did not grant stock options during the nine months ended September 30, 2025. A summary of the Company’s option activity related to options to employees and directors, and … Compensation expense for restricted stock is based on fair market value at the grant date. ​ ​ ​ ​ ​ ​ ​ ​ ​      ​      ​      Weighted Average ​ ​ ​ ​ ​ ​ Remaining ​ ​ Number of Shares ​ Weighted Average ​ Contractual ​ ​ of Restricted ​ Grant … n® as a treatment for AD. On August 15, 2022, we announced our decision to submit a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for NurOwn® for the treatment of ALS. On September 9, 2022, we filed a BLA to the FDA for NurOwn® for the treatment of ALS. On November 10
FDA gives nod to BrainStorm for ALS trial after Phase III flop Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Product & Ser … Chain Data Management Medical Devices Latest Ollin Biosciences secures $330m to fund Phase III OLN324 trials Viking Therapeutics commences Phase I trial of VK3019 Ascletis receives FDA clearance for Phase I trial of obesity treatment Themes Sections Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Foreign Direct Investment Latest How wearables can unlock their full potentia … tarted in February 2021 when the FDA advised against filing a Biologics License Application (BLA). In August 2022, the company went back to the FDA with Phase III trial (NCT03280056) data, which did not meet the primary endpoint , with the BLA submission being rejected later that year. The company then used the FDA’s File Over Protest procedure, to secure an advisory committee (AdCom) meeting . The committee voted 17-1 against NurOwn’s efficacy for mild to moderate ALS, citin
Bairex | Latest Updates --> You are using an outdated browser. Please upgrade your browser to improve your experience. SUBSCRIBE For COVID-19 Related Questions: Email [email protected] or ASK NOW! Home Latest on COVID-19 End Avoidable Blindness Neurodegenerative Diseases Cancer Care Cardiac Care BOOKS About us Careers Courses Events News Telemedicine TeleRadiology TeleInfectious D/Covid-19 TeleOncology TeleNeurology / Ophthalmology TeleCardiology TeleCardiology --> Login/Register SUBSCRIBE Home Latest on COVID-19 End Avoidable Blindness Neurodegenerative Diseases Cancer Care Cardiac Care … zuela Vietnam Yemen Zambia Zimbabwe State Type your Question and/or Concern ... SUBMIT Close LATEST ON Neurodegenerative Diseases Home Latest on Neurodegenerative Diseases Mar 11 2024 Drugs for Alzheimer’s Disease: what’s coming? With population aging, the number of people with dementia is expected to increase o... --> → Read more Dec 18 2023 APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry | Genetics and Genomics | JAMA Neurol … ld an Advisory Committee Meeting to discuss the company's Biologics License Application for NurOwn for the treatment of amyotrophic lateral sclerosis. BrainStorm Cell Therapeutics Inc. said Monday that the U.S. Fo... --> → Read more Mar 28 2023 A Step Forward in the Fight Against Dementia— Are We There Yet? Is there anything you can do to slow down the cognitive decline?” Each of us fields this... --> → Read more Jan 20 2023 U.S. Food … onal cataract surgeries. To enable this to happen, we need to raise $100,000 to fund the effort. I've seen first-hand the immeasurable joy radiating from Ethiopians and Eritreans after having their sight restored by HCP, and a world of darkness is washed away with the careful touch of a surgeon. I support the Himalayan Cataract Project because we can solve needless blindness in our lifetime, but only if we work together. Please join in me supporting such a critical cause and … s in Science: Honoring Professor Asmeret Asefaw Berhe as a 2020 Great Immigrant Award Recipient Latest Events 14th Annual Scientific Conference and General Meeting Mental Health and Coping during Covid-19 A Timely COVID-19 Discussion in Tigrignia EADSG | East African Diabetes Study Group Cancer in Africa: Innovation, Strategies, Implementation 55
--> How to Establish a Partnership – HCPSS --> skip to main content HCPSS Main Menu Languages Español 中文 한국어 Chin For You Parents Students Staff & Retirees About Schools Academics Supports News Search —— Page Template —— --> How to Establish a Partnership Use these steps as a guide to building a successful, rewarding partnership. Step 1: Understand the Commitment Consider your organization’s goals and partnership interests, and then choose a school or program that would make a good match. A relationship is characterized as a “partnership” when it is: tw … iscuss your proposed partnership idea. Step 4: Look Ahead After discussing your proposal with the Partnerships Office, next steps may include: Planning : Meet with your partner to brainstorm. Focus the partnership on enhancing student achievement and supporting safe, nurturing schools. Identify specific activities and respective responsibilities. Make sure the partnership is a good “fit” – built on common values and mutually beneficial goals. Identify potential benefits that
Brainstorm Software License Agreement – Brainstorm Solutions Virtual studios Motion graphics News & sports Election graphics Presentations Augmented reality Weather Entertainment Education Products InfinitySet Aston eStudio Edison Neuron OnDemand AstonElections AstonWeather Plugins Services Corporate About us R&D Work with us Contact Where to buy Support | Reseller zone Solutions Virtual studios Motion graphics News & sports Election graphics Presentations Augmented reality Weather Entertainment Education Products InfinitySet Aston eStudio Edison Neuron OnDemand AstonElect … se to use the Software the Customer agree as follows: Section 1. License Grant Brainstorm grants to the Customer a non-exclusive, non-transferable license to use the Software on the specified computer hardware, (or in the case of a Quotation for Customer evaluation, a temporary non-exclusive, non-transferable license for use during the evaluation period), upon the terms and conditions of this Agreement. Wherever the term “sale” or “purchase” of the Software is referred … nstorm will attempt to answer the Customer’s questions relating to the software application where Brainstorm is able to duplicate the issue on a certified hardware configuration. For Edison PRO customers, Brainstorm offers a free-of-charge web-based support scheme as standard support, accessible from the Support Site or the Brainstorm Users Blog. Such customers can also contract Brainstorm Customer Support Services for Edison PRO as a separate item, based on the then publishe
Our Impact | Center for Community Engagement | Seattle University Skip to main site navigation Skip to main content Skip to footer content Click to visit the home page News Events Athletics Cornish College Info For Admitted Students Alumni Current Students Faculty & Staff Parents & Families Veterans and Military Apply Visit Give Admissions & Aid Apply Now Undergraduate Admissions Graduate Admissions International Admissions Transfer Admissions Executive & Professional Admissions Tuition & Fees Financial Aid & Scholarships Request Information Visit & Tour Academics All Programs Schools & Colleg … munity engagement. In 2020, Seattle University was awarded the Richard Guarasci Award for Institutional Transformation , one of only four Impact Awards among a national network of 1,000 Campus Compact member institutions. CCE Executive Director Kent Koth and Erica Yamamura (faculty in College of Education) co-authored a book (Stylus 2018) that profiles Seattle University and four other higher education institutions pursuing place-based engagement. Koth and Yamamura have given … UYI). In 2012, The White House honored Seattle University with the Presidential Award for Community Service , the highest recognition by the federal government to a college or university for its civic engagement, service learning and volunteerism. In 2013, the Youth Initiative made the President’s Higher Education Honor Roll with Distinction for community service. Community engagement as defined by The Carnegie Foundation: “describes collaboration between institut … knowledge and resources with those of the public and private sectors to enrich scholarship, research, and creative activity; enhance curriculum, teaching and learning; prepare educated, engaged citizens; strengthen democratic values and civic responsibility; address critical societal issues; and contribute to the public good.” Additional Accolades "For two decades, the Sundborg Center has been at the forefront of bridging town and gown. The team at CCE has been importa … ty in his President's Address to CCE 20th Anniversary event . Next steps Apply Visit Request Info Admissions & Aid Academics Life at Seattle U Who We Are Information for Admitted Students Alumni Current Students Faculty & Staff Parents & Families Veterans and Military Redhawk Hub Canvas mySeattleU Email ConnectSU Campus Store Careers at Se
EX-10.12 3 v432184_ex10-12.htm EXHIBIT 10.12 Exhibit 10.12 AMENDMENT NO. 3 TO SECOND AMENDED AND RESTATED RESEARCH AND LICENSE AGREEMENT This amendment no. 3 to the Second Amended and Restated Research and License Agreement (this “ Amendment ”) is entered into as of February 18, 2016 by and between Ramot at Tel Aviv University Ltd., a company organized under the laws of Israel with offices at Tel Aviv University, Tel Aviv, Israel (“ Ramot ”) and Brainstorm Cell Therapeutics Ltd., a limited liability company incorporated under the laws of Israel with … p; Section 3.1 of the Agreement (Title, Ramot Technology) shall not apply with respect to the Assigned Rights. Instead, all rights, title and interest in and to the Assigned Rights, and in and to any drawings, plans, diagrams, specifications and other documents containing any of the Assigned Rights shall be owned solely and exclusively by the Company. 3.2 Section 5.1 of the Agreement (License) shall not apply with respect to the Assigned … ; Section 13.4.1 of the Agreement (Termination of Rights) shall not apply with respect to the Assigned Rights. Instead, upon termination by the Company pursuant to Sections 13.3.1, 13.3.2 or 13.3.3 of the Agreement or by Ramot pursuant to Sections 6.4, 13.3.2 or 13.3.3 of the Agreement, the assignment attached to this Amendment as Exhibit A entered into on the date hereof shall automatically enter into effect, and all rights in and to and under the Assigned R … quo; shall mean a claim of a Ramot Patent Right or joint Patent Right or patent application or granted patent owned or controlled by the Company that includes, is supported by or makes use of the Assigned Rights, so long as such claim shall not have been held invalid in a final non-appealable court judgment or patent office decision, in the relevant jurisdiction. 6. Sublicenses Wherever reference is made in the Agreement to a “Sublicen … ting, distribution and/or sale of Licensed Products (regardless of whether such grant of rights or license given or agreement entered into is referred to or is described as a license or as an agreement with respect to the development and/or manufacture and/or sale and/or distribution and/or marketing of Licensed Products), and any option to obtai
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
BrainStorm Gears Up for Phase IIIb NurOwn Trial Amidst ALS Malaise - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pres … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development BrainStorm Gears Up for Phase IIIb NurOwn Trial Amidst ALS Malaise July 22, 2024 | 6 min read | Heather McKenzie Twitter LinkedIn Facebook Email Print A BrainStorm scientist works with NurOwn/ Uri Yablonka After a long and challenging journey for its stem cell therapy Nur … ing ahead to the December PDUFA date, BrainStorm withdrew its Biologics License Application and announced it would conduct a Phase IIIb trial. Nicole Cimbura, co-lead of the Legislative Affairs Team at I AM ALS, told BioSpace she was “devastated” by the verdict. Cimbura said she saw the benefits of NurOwn in her husband, Mike, who received the therapy in a Phase II trial. After treatment with NurOwn, Mike was able to raise his arms above his head, stand without assistance and … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BrainStorm Announces Scientific Presentation at the Annual NEALS Meeting - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinion … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Pharm Country BrainStorm Announces Scientific Presentation at the Annual NEALS Meeting September 30, 2020 | 7 min read Twitter LinkedIn Facebook Email Print BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapies for neurodegenerative diseases, announced the presentation of a poster titled, “ … eat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for FDA approval of autologous MSC-NTF cells in ALS. BrainStorm is also conducting an FDA-approved phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) i … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-to-find-out" > Antibody-drug conjugate Can ADCs be kinder and gentler? Join BioSpace at BIO to find out June 23, 2026 ·&n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Ce … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update August 14, 2023 | 13 min read Twitter LinkedIn Facebook Email Print BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegener … osis (ALS) scheduled for September 27, 2023 BrainStorm's Biologics License Application (BLA) for NurOwn has a Prescription Drug User Fee Act (PDUFA) action date targeted to occur by December 8, 2023 Company prepares for ADCOM date presentation and builds resources for FDA review and decision Conference call and webcast at 8:00 a.m. Eastern Time today NEW YORK , Aug. 14, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer … acy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive MS and was supported by a grant from the National MS Society (NMSS). Notice Regarding Forward-Looking Statements This press release contains "forward-lookin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BrainStorm Cell Therapeutics Inc. Announces New CEO - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business BrainStorm Cell Therapeutics Inc. Announces New CEO October 12, 2007 | 4 min read Twitter LinkedIn Facebook Email Print NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI - News), a leading developer of adult stem cell technologies and therape … of the Israeli Defense Forces for over 28 years, Mr. Efrati received a special award for Creative Thinking. Prior to joining BrainStorm, Efrati served as VP sales, business development and marketing for NICE SYSTEMS (NASDAQ:NICE - News) government project division for seven years. Mr. Efrati is one of the founders and CEO of TeleFlight Technologies, a technological company specializes in research and development of micro electronics solutions that is mainly oriented for unma … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cel … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial June 26, 2024 | 4 min read Twitter LinkedIn Facebook Email Print BrainStorm Cell Therapeutics Inc. ment with the U.S. Food and Drug Administration (FDA) on the Chemistry, Manufact … acy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989), and another grant from the ALS Association and I AM ALS. BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive MS and was supported by a grant from the National MS Society (NMSS). Notice Regarding Forward-Looki … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BrainStorm levels up, bringing on former FDA leader Peter Pitts for new ALS bid - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development BrainStorm levels up, bringing on former FDA leader Peter Pitts for new ALS bid June 2, 2026 | 5 min read | Heather McKenzie Twitter LinkedIn Facebook Email Print iStock, cagkansayin For Peter Pitts, a former associate commissioner at the FDA, the appointment to the board … December 2023 PDUFA date, BrainStorm elected to withdraw the biologics license application and conduct a Phase 3b trial—an endeavor it’s been raising money for ever since. In June 2025, a new opportunity appeared to present itself when the biotech reported data from 10 Phase 3 participants who entered NurOwn’s expanded access program (EAP). Nine of these patients survived more than five years from ALS symptom onset, with median survival of 6.8 years. According to other publi … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
--> --> Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn® --> --> Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS About Progressive MS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Toggle Overview N … eat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with prog
2026 NAB Show | Sanken Microphones and Brainstorm Electronics Apr. 18- 22 Las Vegas, NV Menu See more links My Planner My Profile Recommendations Sign Out myNAB Show See more links My Planner My Profile Recommendations Sign Out Explore Floor Plan Find Exhibitors & Products Featured Exhibitors Find Sessions & Speakers Visit NABShow.com Sending Email... There are no available appointments for this exhibitor. Saving... Saving... Sanken Microphones and Brainstorm Electronics Booths Booth Locations North Hall — N1808 Notes Create or log in to myNAB Show to see Notes . Company Information Abou
No More Excuses! ALS Watch Dog Group | Is this the funding needed
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Mu … 799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Welcome to the Brainstorm adding wdth to play with stretch --> --> --> --> Magazine Articles by Topic Read the Magazine Magazine Subscriptions Renew, Update Address, Back Issues Portable/Modular Awards Enter Your Exhibit Corporate Event Awards Nominate Your Event All Awards Programs Free Newsletters Media Kit Education Certification Power Week EXHIBITOR LIVE 2027 Denver Save Your Seat! Trade Show Foundations A Full Day of the Basics eTrak Online Education Certification Certified Trade Show Marketer An overview of CTS … ucers Rental Modular Exhibits Convention Centers All Companies News Latest News Submit Your News Free Newsletters Sign In Sign In Sign Out What's Happening Now EXHIBITOR LIVE 2027 - Denver, Colorado Save Your Seat and Save $645! eTrak University-Affiliated Online Learning Registration is Open! Submit your Session Proposal for EXHIBITOR LIVE 2027 --> Breaking News: IAEE Completes Acquisition of Exhibitor Group --> Corporate Event Awards Entry is Open Nominate Your Event! Trade
--> --> Investors & Media - BrainStorm Cell Therapeutics - Annual Reports --> --> Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS About Progressive MS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Toggle Overview News Events & Presentations Stock Information Financial Reports
BrainStorm Adoption Platform <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1386548816544472&amp;ev=PageView&amp;noscript=1"> --> Use Cases Product Pricing Resources Learn Blog Company BrainStorm Login --> The #1 LMS for end-user training BrainStorm makes it easy on IT and HR to onboard new users, transition users to new applications, and help them get more from their existing software licenses. Take advantage of your organization's fully funded account today. Book a demo Try for free Trusted by "As CIO at Oracle, my top priority was getting th … n easy-to-manage platform that's user-friendly. Successfuly guide users through application rollouts and cutovers with BrainStorm's automated emails and course curation. Become a partner Who uses it? Remediating software misuse BrainStorm helps improve end-user work habits, making workplaces more collaborative, productive, and secure. Use data to group users in need of coaching, assign remedial training, and then track completion. BrainStorm helps users make course correction
--> --> Investors & Media - BrainStorm Cell Therapeutics - SEC Filings --> --> Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS About Progressive MS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Toggle Overview News Events & Presentations Stock Information Financial Reports &am
BrainStorm CEO awarded 1.8M restricted stock units | BCLI Insider Trading --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks … filing. BrainStorm Cell Therapeutics President & CEO Chaim Lebovits reported an award of 1,800,000 shares of common stock in the form of restricted stock units under the company’s equity plan. The RSUs vest 50% on the February 26, 2026 grant date and 50% on the six‑month anniversary, contingent on his continued employment. Following this compensation grant, he holds 2,000,960 shares of common stock directly. Positive None. Negative None. Insider Trade Summary 1 transaction re … nsider Lebovits Chaim Role President & CEO Type Security Shares Price Value Grant/Award Common Stock 1,800,000 $0.00 -- Holdings After Transaction: Common Stock — 2,000,960 shares (Direct, null) Footnotes (1) [object Object] Key Figures RSU grant size: 1,800,000 shares Grant price: $0.0000 per share Post-grant holdings: 2,000,960 shares +2 more 5 metrics RSU grant size 1,800,000 shares Restricted stock units awarded to CEO on February 26, 2026 Grant price $0.0000 pe … ry 26, 2026 Grant price $0.0000 per share Stated price for RSU acquisition Post-grant holdings 2,000,960 shares Common stock directly held by CEO after RSU award Immediate vesting portion 50% of award Vests on February 26, 2026 grant date Deferred vesting portion 50% of award Vests on six-month anniversary of grant, subject to employment Key Terms restricted stock units ("RSUs"), vest, Grant, award, or other acquisition, Plan 4 terms restricted stock units ("RSUs& … cost of employee pay. vest financial "The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary" A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’
BrainStorm Therapeutics - BIO International Convention 2026 Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! June 7-10 | Philadelphia Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FAQs International Visitors Why Attend Visa Invitation Letter Request Tips for International Visitors Share On Social Media For Press Media Resource Center Media Registration Engaging with the Media Request Media List Press Releases Stay in Touch Contact Us Join our … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung
--> --> BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials - May 27, 2025 --> --> Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS About Progressive MS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Toggle Overview News Ev … 799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging
BrainStorm HIMSS 2026 Log in Language Resource center Contact app support Legal Home What's On the Schedule? Who's in The Exhibit Hall BrainStorm Exhibitors 6442 Bookmark Information BrainStorm is different. One part communications engine, one part learning management, and one part analytics, BrainStorm is THE behavior change platform for software vendors, software customers, and software end users to adopt and engage in their AI. Exhibitor Categories Applied AI Cybersecurity HIPAA/GDPR Compliance & Management User Experience & Accessibility Contact details https://www.brains
BrainStorm Summit – End Childhood Brain Cancer Skip to content Home BrainStorm Connect Sponsorship Opportunities Past Years Facebook Twitter Instagram Toggle Menu New Location! DoubleTree by Hilton – McLean, VA Register Book Your Room Sponsor the BrainStorm Summit About Us Our 5th Annual Event! New Location Wednesday, September 16th – Friday, September 18th This summit will bring experts in the field of pediatric neuro-oncology and many opportunities for anyone wanting to learn more about the #1 disease-related killer of our children: Brain Cancer! Important Links Home Contact Info
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Brainstorm | Real-Time 3D Graphics & Virtual Production Software for Broadcast Solutions Virtual studios Motion graphics News & sports Election graphics Presentations Augmented reality Weather Entertainment Education Products InfinitySet Aston eStudio Edison Neuron OnDemand AstonElections AstonWeather Plugins Services Corporate About us R&D Work with us Contact Where to buy Support | Reseller zone Solutions Virtual studios Motion graphics News & sports Election graphics Presentations Augmented reality Weather Entertainment Education Products InfinitySet Aston eStudio Edison
Brainstorm School Online Courses Concept Art Games & Film Foundations 2D/3D Concept Design Visual Development Storyboard Flash Mentorships Workshops What We Do Instructors FAQ Contact Us Register Now TAKE A CLASS WITH SPENCER WAN Starts June 27th – Limited Spots Available Class starts in: Day(s) : Hour(s) : Minute(s) : Second(s) Register Now LEARN FROM THE INDUSTRY Leading Professionals in Creative Fields $ Workshops $ Mentorships Find a course Empower Your Creative Career REGISTRATION IS NOW OPEN SUMMER TERM BEGINS MAY 18, 2026 Register Today to start your journey in concept art, design, … mni who share your artistic goals and encourage you to push your craft further. Apply what you learn in hands-on assignments that mirror industry workflows, preparing you for the challenges and expectations of professional studios. Explore Courses Brainstorm completely changed how I approach design. Learning from working professionals gave me the skills and confidence to land my first job at a game studio right after graduation. Alex R. Concept Art Graduate The online format
Introduction - Brainstorm Toggle sidebar Toggle navigation Comments Search: Menu Attachments Versions Raw Text Print View Login Software Introduction Gallery Download Installation Users Tutorials Forum Courses Community Publications Development What's new What's next About us Contact us Contribute News --> Star Follow Follow @brainstorm2day Follow --> Next courses & demos : @CuttingEEG Garden, San Diego, USA: September 23, 2026 --> Problems with automatic updates : Solutions #1 and #2 Software updates : News | Facebook | Twitter | GitHub | LinkedIn Find users by location : Introduction Bra … ind users by location : Introduction Brainstorm is a collaborative, open-source application dedicated to the analysis of brain recordings: MEG, EEG, fNIRS, ECoG, depth electrodes and multiunit electrophysiology. The application is free; a Matlab license is not required to use it. Our objective is to share a comprehensive set of user-friendly tools with the scientific community using MEG/EEG as an experimental technique. For clinician-scientists and researchers, the main advan … It is also good offline reading to get an overview of the main features of the application. Tadel F, Baillet S, Mosher JC, Pantazis D, Leahy RM (2011) Brainstorm: A User-Friendly Application for MEG/EEG Analysis Computational Intelligence and Neuroscience, vol. 2011, ID 879716 What you can do with Brainstorm MEG/EEG/iEEG recordings Digitize the position of the EEG electrodes and the subject's head shape | Polhemus | 3D Scanner Support for multiple modalities | MEG , EEG , sE … k access to comparisons between subjects or conditions Graphical batching tools Apply the same process to many files in a few clicks | link Automatic generation of scripts to perform full analysis | link Flexible plug-in structure that makes the software easy to extend | link Head modeling MEG: Single sphere, overlapping spheres | link EEG: Berg's three-layer sphere, Boundary Element Models (with OpenMEEG ) and the Finite Element Models (with DUNEuro ) sEEG/ECoG: Infinite hom … follows a continuous development and release model . Brainstorm is updated on a rolling basis to ensure that users have access to the latest features, improvements and bug fixes as soon as they are ready. These updates are regularly published on the Brainstorm GitHub repository , and the version in the download page are updated everyday. Updates
Brainstorm (1983 film) - Wikipedia Jump to content Main menu Main menu move to sidebar hide Navigation Main page Contents Current events Random article About Wikipedia Contact us Contribute Help Learn to edit Community portal Recent changes Upload file Special pages Search Search Appearance Donate Create account Log in Personal tools Donate Create account Log in Contents move to sidebar hide (Top) 1 Plot 2 Cast 3 Production Toggle Production subsection 3.1 Natalie Wood's death 3.2 Effects 4 Soundtrack 5 Reception and legacy 6 Accolades 7 See also 8 References 9 External links Toggle the table … rainstorm was composed and conducted by James Horner . The score won the Saturn Award for Best Music in 1983. The Varèse Sarabande album/CD release is a re-recording with the London Symphony Orchestra , produced shortly before the original theatrical release. [ citation needed ] Reception and legacy [ edit ] Brainstorm was released on September 30, 1983, almost two years after Wood's death. However, it opened on a small number of screens and with little publicity desp … 83 science fiction films English-language science fiction thriller films Saturn Award–winning films Hidden categories: Articles with short description Short description matches Wikidata Use mdy dates from February 2026 Use American English from January 2025 All Wikipedia articles written in American English Template film date with 1 release date All articles with unsourced statements Articles with unsourced statements from July 2024 Pages using multiple image with zero images … the Creative Commons Attribution-ShareAlike 4.0 License ; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy . Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. , a non-profit organization. Privacy policy About Wikipedia Disclaimers Contact Wikipedia Legal & safety contacts Code of Conduct Developers Statistics Cookie statement Mobile view Search Search Toggle the table of contents Brainstorm (1983 film)
BrainStorm Cell Therapeutics – NurOwn Skip to primary navigation Skip to main content Skip to primary sidebar Skip to footer Email Facebook LinkedIn Twitter YouTube Search this website International Alliance of ALS/MND Associations Members' Login Contact Join the Alliance Donate Understanding ALS/MND What is ALS/MND Genetics Navigating the Community Find a Member Association Support for PALS & CALS Fundamental Rights for People with ALS/MND and Caregivers Research Voice Preservation Open Science Open Label Extension Expanded Access Understanding ALS/MND Research Improving Regulatory … rs ALS/MND Connect March of Faces Patient Fellows Program Alliance Fellows SEED Grant Program International Symposium About Who We Are ALS/MND Health Literacy Map Board of Trustees Advisory Councils/Committees Scientific Advisory Council PALS and CALS Advisory Council Advocacy and Public Policy Forum Research Directors Forum Governance Committee Finance Committee Staff History Archives Newsletters Meetings Awards Forbes Norris Award Humanitarian Award Allied Health Profession … etings Awards Forbes Norris Award Humanitarian Award Allied Health Professional Award Student Innovation Award Members Member Registration Forgot Password BrainStorm Cell Therapeutics – NurOwn Background The BrainStorm treatment regimen consists of a person’s own stem cells (called autologous) being removed from bone marrow and then grown outside of the body in the presence of a chemical owned by the company, called NurOwn, which aims to increase the stem cells’ ability to ma … October 18th, Brainstorm announced they were withdrawing the Biologics License Application (BLA) for NurOwn. The decision to withdraw the BLA was coordinated with FDA and is viewed by FDA as a withdrawal without prejudice. On October 24th, Brainstorm announced a strategic realignment to enable accelerated development of NurOwn® for the treatment of amyotrophic lateral sclerosis (ALS). This realignment is designed to 1) support the company plans to conduct a double-blind, pla
Vendors Attending BrainStorm Vendors Presenting Registration Sessions Vendors Why Sponsor? Sponsorships Booth Pricing Hotel & Accomodations Conference Details FAQ Why Sponsor Brainstorm? For Ed Techs BrainStorm is a conference for K20 technology directors, network administrators, and other IT personnel. This is NOT a conference about curriculum but instead for the bits’n’bytes warriors that support and drive technology in schools. Decision Makers A typical attendee has a high degree of decision-making authority for their school district. Sponsoring and/or exhibiting at BrainStorm guarantees th … ndor Details Door Prizes Vendors may participate in the publicly announced door prize giveaway at the conclusion of the Vendor Expo on Monday. Lead Retrieval Service Exhibitors can collect attendee contact information during the Vendor Expo directly from the attendees. Legal Contract All vendors must agree to this contract when registering. Certificate of Insurance All vendors must submit a Certificate of Insurance to BrainStorm following the requirements in the attached docu … ive payment arrangements. How do we particiapte in the vendor door prizes? Door prize forms will be distributed by a BrainStorm staff member prior to the Expo starting. It is your responsibility to turn in the form to the stage prior to the door prize presentation. The door prize drawing typically starts about 7:00 pm. How do we purchase a speaking slot? BrainStorm does not sell speaking slots/sessions. The steering committee chooses sessions from volunteer … ntations” button on the main event page. That page will list the current year’s deadline. NOTE: If a vendor is chosen to speak, they must purchase a booth or sponsorship. How many companies can occupy one booth? One company per booth! Sponsor/Exhibitor shall not assign to a third party its booth space or any portion of that space without the prior written consent of BrainStorm, which BrainStorm may grant or withhold at its sole discretion. Per our legal contract tha … hat space without the prior written consent of BrainStorm, which BrainStorm may grant or withhold at its sole discretion. If such permission is given, the Sponsor/Exhibitor shall assume full responsibility for the conduct of the assignee and all its representatives. Sponsor/Exhibitor’s product demonstration may in no way interfere with demonstrat
BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update Accessibility Statement Skip Navigation Back to Global Sites +972-77-2005042 Blog Journalists GDPR Send a Release News Products Contact Hamburger menu Send a Release Telephone +972-77-2005042 from 8 AM - 11 PM IL Contact Contact +972-77-2005042 from 8 AM - 11 PM IL --> Request More Information Journalists GDPR --> Request More Information Journalists GDPR Request More Information Journalists GDPR Request More Information Journalists GDPR BrainStorm Cell Therapeutics Announces Full Year 2025 Fi … 799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging … with the FDA will have productive outcomes, whether Brainstorm can successfully fund and complete the Phase 3b ENDURANCE study of NurOwn and other factors detailed in BrainStorm's annual report on Form 10-K available at http://www.sec.gov . These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, an … eden United Kingdom United States Do not sell or share my personal information: Submit via [email protected] Call Privacy toll-free: 877-297-8921 Global Sites Asia Brazil Canada Csezh Denmark Finland France Germany India Israel Italie Mexico Middle East Netherlands Norway Poland Portugal Russia Slovakia Spain Sweden United Kingdom United States +972-77-2005042 from 8 AM - 11 PM IL Terms of Use Privacy Policy Information Security Policy Site Map Cookie Settings Cop
--> --> Investors & Media - BrainStorm Cell Therapeutics - Documents & Charters --> --> Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS About Progressive MS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Toggle Overview News Events & Presentations Stock Information Financial Re
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Leadership - BrainStorm – Discover, Innovate, Deliver – Delivering on the Promise of Cellular Therapeutics Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Toggle Overview News Events and Presentations Stock Information Financial Report
--> --> Investors & Media - BrainStorm Cell Therapeutics - Press Releases --> --> Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS About Progressive MS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Toggle Overview News Events & Presentations Stock Information Financial Reports … eat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis. The Phase 2 study of autologous MSC-
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
BrainStorm Announces Appointment of Chaim Lebovits as Chief Executive Officer Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Mul … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Chaim Lebovits - BrainStorm – Discover, Innovate, Deliver – Delivering on the Promise of Cellular Therapeutics Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Toggle Overview News Events and Presentations Stock Information Financial Re
Petition · Help ALS patients - Remove Chaim Lebovits as CEO of Brainstorm Cell Therapeutics, Inc. - United States · Change.org Skip to main content My petitions Search Start a petition Log in Help ALS patients - Remove Chaim Lebovits as CEO of Brainstorm Cell Therapeutics, Inc. Help ALS patients - Remove Chaim Lebovits as CEO of Brainstorm Cell Therapeutics, Inc. Decision Maker: Brainstorm Cell Therapeutics, Inc The Issue Having lived with ALS for over a decade, I have personally experienced the excruciating waiting game for a treatment that could potentially change my life. Like many others, … te is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Español (España) Français English (Australia) English (Canada) English (United Kingdom) English (India) English (United States) Español (Argentina) Русский Português (Brasil) Italiano Türkçe Bahasa Indonesia 日本語 ภาษาไทย Deutsch हिन्दी English (United States) Deutsch English (Australia) English (Canada) English (India) English (United Kingdom) English (United States) Español (Argentina) Espa
Team - Brainstorm Ventures Portfolio Team Menu Team Ariel Jadus Managing Partner Ariel Jadus Managing Partner Ariel has fifteen years of experience as a venture capitalist and impact investor. Ariel joined Brainstorm Ventures after its inaugural fund and has co-led all of its subsequent funds and special purpose vehicles (SPVs). Ariel serves on the board of Defy Ventures, a nonprofit that provides entrepreneurship training to incarcerated people. Ariel is a Kauffman Fellow and has been a Mentor to three more recent Fellows. He also serves as Mentor for Techstars Miami, Venture Forward, Unreaso … in & Company. He advised clients, such as the Gates Foundation and Hispanic Scholarship Fund, on their investment and growth strategies. Ariel briefly led the United Nations Development Programme’s Growing Sustainable Business Initiative in Venezuela. Prior to business school, he worked in various capacities at Intel Corporation. Ariel received his MBA from Wharton and holds bachelor’s and master’s degrees in industrial engineering from UC Berkeley and Georgia Tech, respe
--> --> BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update - Aug 14, 2025 --> --> Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS About Progressive MS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Toggle Overview News Events … 799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging
BrainStorm Summit - Neev Kolte & Brave Ronil Foundation Menu Home About Us Meet Neev & Ronil Our Mission Board of Directors Medical Advisors Affiliations What’s DIPG? What is DIPG? Treatment for DIPG Best Practices Brave Kids Our Impact Impact Statement 2025 Grants CureFest BrainStorm Summit Family Support BORN Community Outreach Resources Events Youth Chapter Sponsors 2025 2024 Our Community Donation Options Contact DONATE NOW Menu Home About Us Meet Neev & Ronil Our Mission Board of Directors Medical Advisors Affiliations What’s DIPG? What is DIPG? Treatment for DIP
Brainstorm Cell Therapeutics CEO Acquires Shares — TradingView News Search Products Community Markets Brokers More EN Get started News / TradingView / Brainstorm Cell Therapeutics CEO Acquires Shares Brainstorm Cell Therapeutics CEO Acquires Shares Less than 1 min read Reporter Name Lebovits Chaim Relationship President & CEO Type Purchase Amount $11,308 SEC Filing Form 4 Brainstorm Cell Therapeutics President & CEO, Chaim Lebovits, purchased a total of 23,836 shares of common stock on September 30 and October 1, 2024, for a total amount of $11,308. The purchase price per share was a w
--> --> Investors & Media - BrainStorm Cell Therapeutics - Press Releases --> --> Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS About Progressive MS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Toggle Overview News Events & Presentations Stock Information Financial Reports … linical and biomarker analyses in support of the filing of a biological license application with the goal of bringing an innovative and much needed treatment option to ALS patients.” About NurOwn® NurOwn® (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expand … nistration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm received U.S. FDA clearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
No More Excuses! ALS Watch Dog Group | “We are committed to fortifying our technological advancements with robust intellectual property strategies," stated BrainStorm's CEO, Chaim Lebovit...
Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos A … 799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
--> --> BrainStorm Cell Therapeutics to Present at Rodman & Renshaw 17th Annual Global Investment Conference - Sep 2, 2015 --> --> Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS About Progressive MS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Toggle Overview News Events & P
--> --> Investors & Media - BrainStorm Cell Therapeutics - Overview --> --> Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS About Progressive MS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Toggle Overview News Events & Presentations Stock Information Financial Reports &
--> --> BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025 - May 7, 2025 --> --> Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS About Progressive MS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Toggle Overview News Event … lis , CPA, MBA, Interim Chief Financial Officer. Participants are encouraged to submit their questions in advance of the call by sending them to: [email protected] . Questions should be submitted by 5:00 p.m. Eastern Time on Monday, May 12, 2025 . Investors may access the conference call by dialing the following numbers: Participant Numbers: Toll Free 888-506-0062 International 973-528-0011 Participant Access Code 621608 Webcast https://www.webcaster4.com/Webcast/Page/235 … 799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging
--> --> BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair - Jun 20, 2023 --> --> Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS About Progressive MS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Toggle Overview News Events & Presentation … acy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive MS and was supported by a grant from the National MS Society (NMSS). Safe-Harbor Statement Statements in this announcement other than historical data and in
--> --> Investors & Media - BrainStorm Cell Therapeutics - Press Releases --> --> Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS About Progressive MS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Toggle Overview News Events & Presentations Stock Information Financial Reports … ess development activities across the U.S. Dr. Shah completed his post-doctoral fellowship in Infectious Diseases from Stanford University School of Medicine . He holds a Ph.D. in Microbiology from the University of Mississippi Medical Center and a M.B.A. in Finance from the Wharton School , University of Pennsylvania . “I am very pleased to announce that Preetam Shah , Ph.D., M.B.A. has joined the Senior Management Team of BrainStorm … nistration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis. The Phase 2 study of autologous MSC-
BrainStorm Announces Formation of Scientific Advisory Board and Appoints Neuroscientist Jerold Chun, M.D., Ph.D., to Chair - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busine … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business BrainStorm Announces Formation of Scientific Advisory Board and Appoints Neuroscientist Jerold Chun, M.D., Ph.D., to Chair March 12, 2018 | 3 min read Twitter LinkedIn Facebook Email Print BrainStorm Cell Therapeutics Inc. announced the formation of its Scientific Advisory Board (SAB) and the … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Sponsorship Opportunities at Eagle Creek Park Search for: Visit Hours Fees Maps Activities Events Rentals Earth Discovery Center Ornithology Center Rules + FAQ Admission Entry Fees Foundation Pass Partner Pass News Blog Newsletter Podcast Video Facebook Instagram Support Become A Member Donate Merch Volunteer Partner Sponsor Legacy About Mission Projects Annual Report History Team Board Members Members Member News Member Events Member Sign Up Member Login > Contact Emergency Park Foundation Other Subscribe BUY A FOUNDATION PARK PASS Partners + Sponsors Adam Hibshman Marketing and Program Manag
Partner With Us | Cybersecurity and Privacy Institute | University of Waterloo Skip to main content Jump to Jump to Admissions About Waterloo Faculties & Academics Offices & Services Support Waterloo Open Search Location Search for Search Location On all sites On this site Cybersecurity and Privacy Institute Menu Cybersecurity and Privacy Institute Home About About Our people Staff Researchers Faculty Advisory Committee Student Members Research Accomplishments Partner With Us National Cybersecurity Consortium Resources Students Students Scholarships Current Students Digital OverGround - CPI St … for: a named lecture series student awards (e.g., Best CPI dissertation/thesis award) a named Research Chair may choose to set up a named Faculty Fellow which will contain the name of the sponsor in the title (i.e., “<sponsor> Faculty Fellow in Cybersecurity and Privacy”) other possibilities, to be discussed with the Partner Discuss deeper engagement with CPI and the Partner, e.g., Co-develop a professional upskilling cybersecurity/privacy course in partnership with Wa … holastic Sponsor $15,000+ per year Named student awards Either a named graduate scholarship ($10,000 each) Or up to 5 named undergraduate awards ($1,000 each), if available Invitation to CPI’s Annual Conference and meet-and-greet with CPI scholarship recipients Dissemination of internship and job opportunities in CPI public newsletter Annual meeting with CPI to discuss Sponsor needs for research and consulting Sponsor logo on CPI website, reports, and other collateral materia … ear) Work with the faculty to launch larger initiatives such as a joint project proposal to the National Cybersecurity Consortium, or other public funding programs Invitation to CPI’s annual October event(s) Listed as a sponsor on CPI website, reports, and other collateral materials developed Ability to advertise company’s open positions on CPI website Possibility to have a short-term graduate student internship option Contact us about Sponsorship Opportunities Discover Canad
--> --> BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology - Dec 3, 2024 --> --> Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS About Progressive MS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Toggle Ov … ice of Allowance from the U.S. Patent & Trademark Office (USPTO) for patent application 16/981,757 which covers its proprietary exosome technology. The patent describes the composition and method of BrainStorm's unique exosomes that are isolated from the secretome of MSC-NTF (mesenchymal stem cells that secrete neurotrophic factors). MSC-NTF -derived exosomes are produced in bioreactors and contain cargo (i.e. active biological molecules) that includes at least one of the
Executive sponsorship: why it makes or breaks AI rollouts <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1386548816544472&amp;ev=PageView&amp;noscript=1"> Use Cases Software Vendors Customer Education Customer Success Customer Onboarding User Activation Product Adoption See All Software Customers IT Teams HR and L&D Teams AI Adoption Change Management Remediation End-User Adoption See All Partners Service Providers Systems Integrators Channel Resellers MSSPs Clueso Product Features Adaptive Workflows Admin Portal Communications End-User Por … e, adoption accelerates. Why AI rollouts need executive sponsors more than ever Rolling out AI tools is not like deploying a new email client. It changes how people work, how decisions get made, and what skills matter. That kind of change creates real anxiety. A 2025 survey found that 89% of workers are concerned about how AI will affect their jobs. Nearly a third actively resist their company's AI initiatives. Without a credible leader out front, framing the change and answe
--> --> BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB - Jul 17, 2025 --> --> Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS About Progressive MS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Toggle Overview News Events & Presentations Stock I … 799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging
--> --> BrainStorm Announces Formation of Scientific Advisory Board and Appoints Neuroscientist Jerold Chun, M.D., Ph.D., to Chair - Mar 12, 2018 --> --> Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS About Progressive MS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Toggle Overv
BrainStorm Therapeutics - BIO International Convention 2026 Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! June 7-10 | Philadelphia Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FAQs International Visitors Why Attend Visa Invitation Letter Request Tips for International Visitors Share On Social Media For Press Media Resource Center Media Registration Engaging with the Media Request Media List Press Releases Stay in Touch Contact Us Join our … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung
%PDF-1.3 %��������� 3 0 obj > stream x�[�r��}�W�K�v�]��!YV,_d;qW�*� R*;��Jb)������@f�\�`.=}����o��oyӵE?�m�w�p�����vE��݆�nl������,j�%�K�O�iDz˩�l�&ﺢ����x�՟�������?����1/��7ƙR�ϯ�}��/�։��/>���G�S� ߡ�,��?��P��E;�E߁ Pxs�?/������]��~�>�� �e �]~����� w?�ͷ������s�oϞ�� b :F��'r����!��]��V�>��_�����s��4j���Y�$H|���YE������)��6V2m��4�1Hgw���� �2�k��pQd�4�{���B�, ̩S�""��m�H��o����n�nU������e Uݹu�*l����|`a1dI�'�C��e]?YN+皙��˝�'�o@E� ���o.v;�]���wgH��lE^ǻ ��,y�r BkP���K2�鵲��r园�&��~D���|�Hp m���͍ >�t mʷE�bݶ�s \� YJ �T C~v�]�����8��J� '���!��X ��3A��I�����8�P�h
--> --> Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market - Feb 20, 2026 --> --> Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS About Progressive MS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Toggle Overview News Events & Presentati … 799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging
The Tim Ferriss Show Transcripts: Tim’s Founder Kitchen — From Brainstorm to the President’s Office in Two Months (Featuring Jake Becraft, Strand Therapeutics) (#868) - The Blog of Author Tim Ferriss Skip to content About Tim Ferriss Bio Causes Contact Tim Ferriss Blog Books Podcast All Episodes All Transcripts Sponsorship & Advertising Sponsors of The Tim Ferriss Show Podcast TV Newsletter FREE NEWSLETTER Search Tim.blog Search Browse by topic: 30-Day Challenges (3) 4-Hour Case Studies (50) Automation (7) COCKPUNCH (7) Comfort Challenges (4) Dance (3) E-mail Detox (23) Entrepreneurship (6 … ears is a drug called KEYTRUDA from Merck. Incredible miracle drug, won a Nobel Prize a few years ago. In melanoma, if you respond to that drug, a lot of patients do. That’s great. If you don’t, the likelihood of survival begins to diminish very quickly. And this patient had had KEYTRUDA. They had had a whole number of other drugs through many, what they call, lines of therapy. You’d get a drug, your cancer responds or it doesn’t. If it doesn’t r … ve cured mice of cancer. There’s millions of them. There could be a Nobel Prize every five minutes for someone who’s cured a mouse of cancer. Our goal is to cure human beings of human-being cancer. Our goal is to cure human beings of human-being diseases, and do so in a safe, effective, scalable way that impacts a person’s life as little as possible. And that is what we’re building. We’re building as a commercial organization. We’re buildin … sidizes the — it’s sort of like Uber Black subsidizing UberX. There is an application there, but if it’s fundamentally incompatible with current healthcare, you’re trying to win a race with your ankles tied together, right? It’s probably not going to happen. And then you have people looking at like, 5-MeO-DMT instead of psilocybin and stuff, and I have my own thoughts on that. But sure, it’s like you look at the failure just real quick, of like, … States right now, you need to write an IND, which is called an initial new drug application to the FDA. It’s very long. I think ours for our first trial was 22,000 pages long. You have to have professional writers, professionalized system, all sorts of very expensive things. Just to write it, it’s millions of dollars. Tim Ferriss: Wow
Become a Sponsor - Country Rising Festival Festival Trainer × Colorado Springs, CO Aug 7, 2026 – Fri Winnipeg, MB Aug 21, 2026 – Fri Buffalo, NY Aug 28, 2026 – Fri × Colorado Springs, CO Aug 7, 2026 – Fri Winnipeg, MB Aug 21, 2026 – Fri Buffalo, NY Aug 28, 2026 – Fri × Lineup Get Involved Vendor Applications Content Creator Collaborations Staff Applications Become a Sponsor Media Opportunities Support Accessibility Contact Legal Terms and Conditions Privacy Policy ★Tickets★ Become a Sponsor Authentic Partnerships and Brand Opportunities Joi … gn. Contact Us CONNECT WITH COUNTRY RISING FESTIVAL Get Involved Apply to be a Vendor Content Creator Collaborations Sponsorship Opportunities Media Opportunities Staff Applications Support Contact Accessibility Legal Terms & Conditions Privacy Policy Sweepstakes Rules Presented by Social House Entertainment – Creators of Tacos and Tequila Festival © 2026 Country Rising Festival. All rights reserved.
Science - BrainStorm – Discover, Innovate, Deliver – Delivering on the Promise of Cellular Therapeutics Skip to content Main Menu Science Menu Toggle Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Pipeline Menu Toggle Pipeline Pipeline Overview Patients & Caregivers Menu Toggle About ALS Clinical Trials Preapproval Access Policies Resources About Menu Toggle Leadership Menu Toggle Executive Team Board of Directors Scientific Advisory Board Careers Investors & Media Menu Toggle Overview News Events and Presentations Stock Information Financial Reports &
Official framework for community sponsorship of the development of specific features - Brainstorm - KDE Discuss = 40rem)" rel="stylesheet" data-target="desktop" /> = 40rem)" rel="stylesheet" data-target="poll_desktop" /> KDE Discuss Official framework for community sponsorship of the development of specific features Brainstorm fundraising , development , funding v4u6h4n May 14, 2026, 11:13pm 1 In line with the recent, very successful, changes made by KDE to it’s fundraising approach, I would like to suggest that additional changes be implemented for managing the sponsorship of the development … t of specific features. Governments and enterprise partners are already able to fund the development of specific features, with the Sovereign Tech Fund investing €1 million being the most recent example. However, as far as I am aware, there are no straight-forward means by which regular members of the community can actually do the same thing; it appears our options are limited to either sponsoring the KDE organisation as a whole or sponsoring a specific KDE application, altho … [Bug Fix] Per-screen virtual desktops mrp May 15, 2026, 3:59am 2 FreeCAD has a grant program , I’m not sure if something similar could work for KDE? I understand their program is basically granting short term contracts to complete a specific task, or to spend a certain amount of time working on a task. You can read the review process and rules here . 1 Like Home Categories Guidelines Terms of Service Privacy Policy Powered by Discourse , best viewed with JavaScript enabled